Navigation Links
Latin American Aortic Stent Graft Market to Reach Over $150 Million by 2015, According to Millennium Research Group
Date:9/23/2010

TORONTO, Sept. 23 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Latin American physicians will increasingly adopt abdominal and thoracic endovascular aortic repair in place of surgical repair through 2015 as awareness of the benefits of endovascular techniques grows and physician training improves.

Thoracic endovascular aortic repair tends to be a slightly more attractive option for physicians and patients because the alternative open surgical procedure is associated with significant mortality, complications, and longer hospital stays. Conversely, newer thoracic aortic stent grafts incorporate features that add to their versatility in treating a variety of thoracic aortic conditions, including aneurysms and dissections. These features include improved deliverability and reliability of stent graft placement, which make it easier for physicians to treat a diverse patient population.  Abdominal endovascular aortic repair, in contrast, will face more competition from surgical options because the latter is not quite as risky in the abdominal aorta compared to in the thoracic aortic. As a result, surgical repair of the abdominal aorta will continue to be preferred in some centers due to the high cost of aortic stent grafts. Although budget constraints among Latin American health care facilities will remain a limiting factor, the aortic stent graft market is set to expand to more than $150 million by 2015.

"Mexico, in particular, has traditionally experienced lower stent graft penetration rates compared to other Latin American countries due to its slow device approval process," says Fareed Hameed, Analyst at MRG.  "Because device approval has lagged behind some other regions, physician training on endovascular repair procedures has also been lower; however, even Mexico will see growth in aortic stent graft procedures of approximately 15% per year through 2015 as manufacturers focus on training individuals in this region."

MRG's Latin American Markets for Peripheral Vascular Devices 2011 report provides critical insight into trends that will fuel market growth for peripheral vascular stents, percutaneous transluminal angioplasty balloon catheters, embolic protection devices, inferior vena cava filters, aortic stent grafts, synthetic surgical grafts, and peripheral vascular accessory devices.  

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101akrohn@mrg.netChris ComfortDecision Resources, Inc. 781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
6. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
7. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
10. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
11. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):